Narrow Results

Diabetic nephropathy (DN) is a common microvascular complication of diabetes mellitus (DM), which can lead to renal failure in diabetic patients. At present, the first-line drugs for DN are mainly the renin–angiotensin system (RAS) inhibitors or angiotensin receptor blockers, and the latest approved aldosterone receptor antagonist finerenone, which delay the progression of DN to end-stage renal disease (ESRD), but the therapeutic effect is still not ideal. With a history of thousands of years, traditional Chinese medicine (TCM) has rich experience in the treatment of DN. Based on the theory of TCM, the clinical treatment of DN mainly focuses on generating fluid and nourishing blood, nourishing Qi and Yin, detoxifying and detumescent. In recently years, the therapeutic effects and mechanisms of TCM prescription, Chinese herbal medicine, and its active components on DN have received extensive attention in new drug development. This paper reviews the research progress of the mechanism of TCM on DN.

Hypoxia is a disorder in which the tissues are not oxygenated adequately. The lack of oxygen may cause irreversible damage to the major organs such as the brain, heart and lungs. In severe cases, coma, seizures, and death may happen. In addition to the routine medication, acupuncture treatment has been applied as a complementary treatment to counter hypoxia. In this paper, the optical fiber acupuncture needle was fabricated using the optical fiber imbedding into the metal capillary tube with needle tip, therefore made it easy to insert into the body for the laser treatment. The laser optical fiber needle treatment to the ST36 acupoint conducted with the laser irradiation intra body. The normobaric hypoxia tolerance test results in mice show that the optical fiber needle treatment to the ST36 acupoint with laser acupuncture appears to improve the tolerance to hypoxia. The mice treated with laser acupuncture expressed high level of IL-1$\beta$ in serum. Our results suggest that laser optical fiber needle acupuncture may serve as a potential treatment for hypoxia.

Rheumatoid arthritis, in short called as RA, is a severe auto-immune condition characterized by thickening of the synovium joints, inflammation and soreness of joints, which subsequently destroys the articular structures. The drug used to treat RA requires the delivery of a formulation in intact form to synovial joints and release of a whole amount of medicine into synovial fluids. Apremilast is an anti-inflammatory drug used to treat arthritis, but its oral drug delivery is limited because of its low bioavailability and side effects. The nanoparticle-based in situ gel helps in prolonged formulation retention, which enables drug release within specific tissues such as cartilage and synovium. The purpose of this research is to formulate and assess the efficacy of a thermosensitive in situ gel of nanosized apremilast for managing RA. A total of nine apremilast- loaded nanoparticles in situ gels designated as F1–F9 were prepared with different ratios of Eudragit RSPO and polyvinyl alcohol using 25% w/v poloxamer 407 and poloxamer 188 as gelling agents. Among the various formulations, F5 showed a particle size of 119 nm, 80.8% EE, 27.54% DL, 37.5 ± 1.7^∘C gelation temperature, 55 ± 1.0 second gelation time and 866 ± 13 cps viscosity, with a better in vitro drug release profile of 75.54% for 24 h by non-Fickian diffusion mechanism; thus, it was chosen as the most productive formulation. In an in vivo study in rats, the optimized formulation reduced inflammation at the test site. The developed nanoparticles in situ gel will be a novel carrier system for drugs used to treat RA.

High and increasing prevalence of neurodevelopmental disorders place enormous personal and economic burdens on society. Given the growing realization that the roots of neurodevelopmental disorders often lie in early childhood, there is an urgent need to identify childhood risk factors. Neurodevelopment is marked by periods of heightened experience-dependent neuroplasticity wherein neural circuitry is optimized by the environment. If these critical periods are disrupted, development of normal brain function can be permanently altered, leading to neurodevelopmental disorders. Here, we aim to systematically identify human variants in neuroplasticity-related genes that confer risk for neurodevelopmental disorders. Historically, this knowledge has been limited by a lack of techniques to identify genes related to neurodevelopmental plasticity in a high-throughput manner and a lack of methods to systematically identify mutations in these genes that confer risk for neurodevelopmental disorders. Using an integrative genomics approach, we determined loss-of-function (LOF) variants in putative plasticity genes, identified from transcriptional profiles of brain from mice with elevated plasticity, that were associated with neurodevelopmental disorders. From five shared differentially expressed genes found in two mouse models of juvenile-like elevated plasticity (juvenile wild-type or adult Lynx1^-/- relative to adult wild-type) that were also genotyped in the Mount Sinai BioMe Biobank we identified multiple associations between LOF genes and increased risk for neurodevelopmental disorders across 10,510 patients linked to the Mount Sinai Electronic Medical Records (EMR), including epilepsy and schizophrenia. This work demonstrates a novel approach to identify neurodevelopmental risk genes and points toward a promising avenue to discover new drug targets to address the unmet therapeutic needs of neurodevelopmental disease.